S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Rare Earth Elements: The Workhorse of The Tech Revolution (Ad)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
Oil spill from capsized barge near Tobago has reached beaches hundreds of miles away, officials say

Syros Pharmaceuticals (SYRS) Competitors

$7.19
-0.15 (-2.04%)
(As of 02/28/2024 ET)

SYRS vs. PRQR, OPTN, RANI, SGMT, DSGN, GLSI, ABEO, PDSB, ADAG, and IVA

Should you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include ProQR Therapeutics (PRQR), OptiNose (OPTN), Rani Therapeutics (RANI), Sagimet Biosciences (SGMT), Design Therapeutics (DSGN), Greenwich LifeSciences (GLSI), Abeona Therapeutics (ABEO), PDS Biotechnology (PDSB), Adagene (ADAG), and Inventiva (IVA). These companies are all part of the "pharmaceutical preparations" industry.

Syros Pharmaceuticals vs.

ProQR Therapeutics (NASDAQ:PRQR) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, community ranking, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

26.2% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 51.3% of Syros Pharmaceuticals shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 10.5% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Syros Pharmaceuticals has a net margin of 0.00% compared to Syros Pharmaceuticals' net margin of -831.30%. Syros Pharmaceuticals' return on equity of -60.65% beat ProQR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ProQR Therapeutics-831.30% -60.65% -21.69%
Syros Pharmaceuticals N/A -155.06%-68.52%

ProQR Therapeutics has higher earnings, but lower revenue than Syros Pharmaceuticals. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ProQR Therapeutics$4.25M38.03-$68.60M-$0.47-4.26
Syros Pharmaceuticals$14.88M10.18-$94.65M-$3.75-1.92

ProQR Therapeutics has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

ProQR Therapeutics presently has a consensus price target of $3.72, suggesting a potential upside of 85.83%. Syros Pharmaceuticals has a consensus price target of $12.50, suggesting a potential upside of 73.85%. Given Syros Pharmaceuticals' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Syros Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ProQR Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Syros Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Syros Pharmaceuticals had 6 more articles in the media than ProQR Therapeutics. MarketBeat recorded 7 mentions for Syros Pharmaceuticals and 1 mentions for ProQR Therapeutics. Syros Pharmaceuticals' average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.51 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
ProQR Therapeutics Very Positive
Syros Pharmaceuticals Positive

Syros Pharmaceuticals received 39 more outperform votes than ProQR Therapeutics when rated by MarketBeat users. Likewise, 64.27% of users gave Syros Pharmaceuticals an outperform vote while only 61.70% of users gave ProQR Therapeutics an outperform vote.

CompanyUnderperformOutperform
ProQR TherapeuticsOutperform Votes
319
61.70%
Underperform Votes
198
38.30%
Syros PharmaceuticalsOutperform Votes
358
64.27%
Underperform Votes
199
35.73%

Summary

Syros Pharmaceuticals beats ProQR Therapeutics on 9 of the 17 factors compared between the two stocks.


Get Syros Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYRS vs. The Competition

MetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$154.63M$6.72B$5.04B$7.52B
Dividend YieldN/A2.81%2.87%3.87%
P/E Ratio-1.926.31179.3913.78
Price / Sales10.18169.053,028.3566.18
Price / CashN/A19.3194.3454.64
Price / Book1.144.764.464.63
Net Income-$94.65M$153.09M$112.73M$211.02M
7 Day Performance1.41%5.95%4.68%2.28%
1 Month Performance-4.39%10.93%9.84%3.39%
1 Year Performance91.22%5.97%12.56%7.45%

Syros Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRQR
ProQR Therapeutics
1.6823 of 5 stars
$1.90
-2.6%
$3.72
+95.6%
-34.0%$153.56M$4.25M-4.04130Analyst Downgrade
OPTN
OptiNose
4.1677 of 5 stars
$1.36
flat
$3.00
+120.6%
+1.4%$152.74M$76.28M-3.40141Upcoming Earnings
News Coverage
RANI
Rani Therapeutics
1.8777 of 5 stars
$3.28
-4.4%
$16.25
+395.4%
-46.0%$164M$2.72M-2.33163Positive News
SGMT
Sagimet Biosciences
2.0023 of 5 stars
$6.98
-7.5%
$50.00
+616.3%
N/A$149.23MN/A0.009Short Interest ↑
Positive News
DSGN
Design Therapeutics
2.2445 of 5 stars
$2.65
+0.8%
$5.67
+113.8%
-59.5%$148.40MN/A-2.0457Short Interest ↑
Positive News
GLSI
Greenwich LifeSciences
2.0582 of 5 stars
$12.94
+15.1%
$36.00
+178.2%
-19.0%$166.28MN/A-18.233Analyst Report
Short Interest ↑
High Trading Volume
ABEO
Abeona Therapeutics
3.8927 of 5 stars
$6.74
-3.9%
$38.00
+463.8%
+201.3%$166.95M$1.41M0.00N/AShort Interest ↑
PDSB
PDS Biotechnology
1.1801 of 5 stars
$5.54
+2.6%
$17.67
+218.9%
-24.1%$172.35MN/A-3.2426
ADAG
Adagene
2.95 of 5 stars
$3.21
+5.6%
$5.00
+55.8%
+92.3%$140.69M$9.29M0.00248Short Interest ↓
News Coverage
Gap Up
IVA
Inventiva
2.5366 of 5 stars
$3.35
+1.2%
$16.00
+377.6%
-33.0%$174.60M$12.83M0.00117Gap Up

Related Companies and Tools

This page (NASDAQ:SYRS) was last updated on 2/29/2024 by MarketBeat.com Staff